AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Getinge

Report Publication Announcement Apr 9, 2010

2917_rns_2010-04-09_6d49b004-5f7c-423d-b56f-87ee64116d8c.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Getinge 9 April, 2010

Getinge announces date of 2010 Q1 report and conference call

GETINGE will issue its Q1 report for 2010 on Wednesday 21st April at 12:00 noon (CET), followed by a conference call at 14:00 (CET), hosted by Johan Malmquist, CEO, and Ulf Grunander, CFO.

To participate in the conference, please dial:

SE: + 46 (0)8 506 269 30 UK: + 44 207 750 9950

13.45 Call in to the conference 14.00 Review of the interim report 14.20 Questions & answers 15.00 Close of the conference

A recorded version of the conference can be accessed for 5 working days on following number:

Sweden: +46 (0)8 506 269 49 UK: +44 207 750 99 28 Access code: 241148#

During the telephone conference a presentation will be held. To access the presentation please use this link: https://www.anywhereconference.com/?Conference=108241148&PIN=599764

For more information please contact: Sylwia Valleberger Investor Relations Phone: +46 (0)35 18 14 61 [email protected]

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.